• About
    • Mission, Vision and Values
    • Team
    • Board of Directors
    • Investors
  • Pipeline
  • VICOMER™ Platform
    • VICOMER™ Platform
    • Scientific Publications
    • Collaborators
  • News
  • Join Our Team
  • Contact Us
VICO Therapeutics
Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington’s Disease and Spinocerebellar Ataxia Types 1 and 3 

Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington’s Disease and Spinocerebellar Ataxia Types 1 and 3 

by VICO Therapeutics | Apr 3, 2023 | Press Release

VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseasesVO659 was designed to preferentially reduce mutant HTT and spare wild-type HTTPhase 1/2a basket trial design and preclinical VO659 data to be presented at CHDI...
Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer

Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer

by VICO Therapeutics | Oct 3, 2022 | Management, Press Release

Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer

Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer

by VICO Therapeutics | Aug 4, 2022 | Management, Press Release

LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ — Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
Sharing RDD Colours in Leiden Science Park

Sharing RDD Colours in Leiden Science Park

by VICO Therapeutics | Mar 1, 2022 | Rare Disease Day

BioPartner, VICO & Ntrans, joined forces this year and shared the colours to help raise awareness for Rare Disease Day, with the aim to help generate change for the 300 million people worldwide living with a rare disease including their families and carers. Our...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

by VICO Therapeutics | Jul 29, 2021 | Press Release

Leiden, The Netherlands, 29 July 2021 –  VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
« Older Entries

© 2020-2023 VICO Therapeutics | All rights reserved | Privacy statement


Designed and developed by Root Agency